Literature DB >> 9795578

Recommendations on the safe and effective use of short-course ZDV for prevention of mother-to-child transmission of HIV.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9795578

Source DB:  PubMed          Journal:  Wkly Epidemiol Rec        ISSN: 0049-8114


× No keyword cloud information.
  7 in total

Review 1.  Global impact of human immunodeficiency virus and AIDS.

Authors:  H D Gayle; G L Hill
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 2.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

3.  THERAPY AND PROPHYLAXIS IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.

Authors:  Mkk Rao; R M Gupta; V C Ohri
Journal:  Med J Armed Forces India       Date:  2017-06-26

4.  Hospital-based evaluation of two rapid human immunodeficiency virus antibody screening tests.

Authors:  R Kannangai; S Ramalingam; P K Selvaraj; S Pradeepkumar; K Damodharan; G Sridharan
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 5.  Economic issues in the prevention of vertical transmission of HIV.

Authors:  A E Ades; J Ratcliffe; D M Gibb; M J Sculpher
Journal:  Pharmacoeconomics       Date:  2000-07       Impact factor: 4.981

6.  Women's views on consent, counseling and confidentiality in PMTCT: a mixed-methods study in four African countries.

Authors:  Anita Hardon; Eva Vernooij; Grace Bongololo-Mbera; Peter Cherutich; Alice Desclaux; David Kyaddondo; Odette Ky-Zerbo; Melissa Neuman; Rhoda Wanyenze; Carla Obermeyer
Journal:  BMC Public Health       Date:  2012-01-11       Impact factor: 3.295

Review 7.  Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention.

Authors:  Ravindra K Gupta; David A M C Van de Vijver; Sheetal Manicklal; Mark A Wainberg
Journal:  Retrovirology       Date:  2013-07-31       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.